Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 557 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Opinion: ‘UK cancer research could be set back years by COVID-19. We must act now’ June 23, 2020 Peace May 19, 2021 Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients... August 6, 2026 An integral part of research September 21, 2022 Load more HOT NEWS COVID-19 Vaccines Are Safe for People Receiving Cancer Immunotherapy, Study Confirms Inspiring the next generation of cancer researchers 25-Year-Old Mom Had Chemo & Surgery, Then Was Told She Never... ACS’s Updated Cervical Cancer Screening Guidelines Explained
